• Novo Nordisk A/S, of Bagsvaerd, Denmark, reported top-line results from a 56-week Phase IIIa trial testing the potential of GLP-1 drug liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with co-morbidities such as prediabetes, hypertension and dyslipidemia. From a mean baseline weight of 106 kg and a body mass index (BMI) of 38 kg/m2, the average weight loss for those treated with liraglutide 3 mg was 8 percent vs. 2.6 percent for the placebo group. The proportion of people achieving a weight loss of at least 5 percent was 64 percent for liraglutide and 27 percent for placebo, while the proportion of those achieving a weight loss of at least 10 percent was 33 percent for liraglutide and 10 percent for placebo. All differences were statistically significant. Liraglutide currently is marketed as Victoza for Type II diabetes.